Literature DB >> 22193422

Autocrine epidermal growth factor receptor ligand production and cetuximab response in head and neck squamous cell carcinoma cell lines.

Goro Oshima1, Johan Wennerberg, Takashi Yamatodani, Elisabeth Kjellén, Hiroyuki Mineta, Anders Johnsson, Lars Ekblad.   

Abstract

PURPOSE: Predictive strategies for the treatment efficacy of cetuximab are currently not available for head and neck cancer. We investigated the correlation between the expression of epidermal growth factor receptor (EGFR) ligands and EGFR expression, and the growth inhibitory activity of cetuximab in a panel of head and neck squamous cell carcinoma (HNSCC) cell lines.
METHODS: The growth inhibiting effect of cetuximab was measured for eight HNSCC cell lines and correlated with the autocrine production of five EGFR ligands as measured by ELISA, and the mRNA expression of two ligands, as measured by quantitative RT-PCR. EGFR expression was assessed by western blot analysis.
RESULTS: There was a good correlation between the expression of four of the EGFR ligands (TGF-α, amphiregulin, epiregulin and epigen) and the growth inhibiting effect of cetuximab. TGF-α had the highest predictive potential but had to be combined with epigen for full prediction. EGFR expression also correlated with cetuximab sensitivity but less clearly.
CONCLUSIONS: The results indicate that the expression of several EGFR ligands has to be used to predict sensitivity to cetuximab in HNSCC. This has to be further evaluated in clinical samples.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22193422     DOI: 10.1007/s00432-011-1127-5

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  28 in total

Review 1.  EGF receptor ligands.

Authors:  Raymond C Harris; Eunkyung Chung; Robert J Coffey
Journal:  Exp Cell Res       Date:  2003-03-10       Impact factor: 3.905

2.  Epidermal growth factor receptor status and persistent activation of Akt and p44/42 MAPK pathways correlate with the effect of cetuximab in head and neck and colon cancer cell lines.

Authors:  Takashi Yamatodani; Lars Ekblad; Elisabeth Kjellén; Anders Johnsson; Hiroyuki Mineta; Johan Wennerberg
Journal:  J Cancer Res Clin Oncol       Date:  2008-09-24       Impact factor: 4.553

3.  p53 mutation and cyclin D1 amplification correlate with cisplatin sensitivity in xenografted human squamous cell carcinomas from head and neck.

Authors:  Eva Henriksson; Bo Baldetorp; Ake Borg; Elisabeth Kjellen; Jan Akervall; Johan Wennerberg; Peter Wahlberg
Journal:  Acta Oncol       Date:  2006       Impact factor: 4.089

4.  Downmodulation of TGF-alpha protein expression with antisense oligonucleotides inhibits proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells.

Authors:  J R Grandis; A Chakraborty; Q Zeng; M F Melhem; D J Tweardy
Journal:  J Cell Biochem       Date:  1998-04-01       Impact factor: 4.429

5.  Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma.

Authors:  Hiromitsu Hatakeyama; Haixia Cheng; Pamela Wirth; Ashley Counsell; Samuel R Marcrom; Carey Burton Wood; Paula R Pohlmann; Jill Gilbert; Barbara Murphy; Wendell G Yarbrough; Deric L Wheeler; Paul M Harari; Yan Guo; Yu Shyr; Robbert J Slebos; Christine H Chung
Journal:  PLoS One       Date:  2010-09-13       Impact factor: 3.240

6.  Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.

Authors:  Shirin Khambata-Ford; Christopher R Garrett; Neal J Meropol; Mark Basik; Christopher T Harbison; Shujian Wu; Tai W Wong; Xin Huang; Chris H Takimoto; Andrew K Godwin; Benjamin R Tan; Smitha S Krishnamurthi; Howard A Burris; Elizabeth A Poplin; Manuel Hidalgo; Jose Baselga; Edwin A Clark; David J Mauro
Journal:  J Clin Oncol       Date:  2007-08-01       Impact factor: 44.544

Review 7.  EGFR-targeting monoclonal antibodies in head and neck cancer.

Authors:  Igor Astsaturov; Roger B Cohen; Paul Harari
Journal:  Curr Cancer Drug Targets       Date:  2007-11       Impact factor: 3.428

8.  PET of EGFR antibody distribution in head and neck squamous cell carcinoma models.

Authors:  Gang Niu; Zibo Li; Jin Xie; Quynh-Thu Le; Xiaoyuan Chen
Journal:  J Nucl Med       Date:  2009-06-12       Impact factor: 10.057

Review 9.  Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer.

Authors:  Alberto Bardelli; Salvatore Siena
Journal:  J Clin Oncol       Date:  2010-01-25       Impact factor: 44.544

10.  Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer.

Authors:  J B Baker; D Dutta; D Watson; T Maddala; B M Munneke; S Shak; E K Rowinsky; L-A Xu; C T Harbison; E A Clark; D J Mauro; S Khambata-Ford
Journal:  Br J Cancer       Date:  2011-01-04       Impact factor: 7.640

View more
  10 in total

Review 1.  Epiregulin: roles in normal physiology and cancer.

Authors:  David J Riese; Richard L Cullum
Journal:  Semin Cell Dev Biol       Date:  2014-03-12       Impact factor: 7.727

2.  The Value of a Novel Panel of Cervical Cancer Biomarkers for Triage of HPV Positive Patients and for Detecting Disease Progression.

Authors:  Norbert Varga; Johanna Mózes; Helen Keegan; Christine White; Lynne Kelly; Loretto Pilkington; Márta Benczik; Schaff Zsuzsanna; Gábor Sobel; Róbert Koiss; Edit Babarczi; Miklos Nyíri; Laura Kovács; Sebe Attila; Borbála Kaltenecker; Adrienn Géresi; Adrienn Kocsis; John O'Leary; Cara M Martin; Csaba Jeney
Journal:  Pathol Oncol Res       Date:  2016-08-06       Impact factor: 3.201

3.  Heat shock protein expression enhances heat tolerance of reptile embryos.

Authors:  Jing Gao; Wen Zhang; Wei Dang; Yi Mou; Yuan Gao; Bao-Jun Sun; Wei-Guo Du
Journal:  Proc Biol Sci       Date:  2014-09-22       Impact factor: 5.349

4.  c-Src activation mediates erlotinib resistance in head and neck cancer by stimulating c-Met.

Authors:  Laura P Stabile; Guoqing He; Vivian Wai Yan Lui; Sufi Thomas; Cassandra Henry; Christopher T Gubish; Sonali Joyce; Kelly M Quesnelle; Jill M Siegfried; Jennifer R Grandis
Journal:  Clin Cancer Res       Date:  2012-12-04       Impact factor: 12.531

Review 5.  Structure and function of epigen, the last EGFR ligand.

Authors:  Marlon R Schneider; Yosef Yarden
Journal:  Semin Cell Dev Biol       Date:  2013-12-25       Impact factor: 7.727

6.  Integrated genomic analysis of colorectal cancer progression reveals activation of EGFR through demethylation of the EREG promoter.

Authors:  X Qu; T Sandmann; H Frierson; L Fu; E Fuentes; K Walter; K Okrah; C Rumpel; C Moskaluk; S Lu; Y Wang; R Bourgon; E Penuel; A Pirzkall; L Amler; M R Lackner; J Tabernero; G M Hampton; O Kabbarah
Journal:  Oncogene       Date:  2016-06-06       Impact factor: 9.867

7.  Preferential Response of Basal-Like Head and Neck Squamous Cell Carcinoma Cell Lines to EGFR-Targeted Therapy Depending on EREG-Driven Oncogenic Addiction.

Authors:  Sylvie Job; Aurélien de Reyniès; Betty Heller; Amélie Weiss; Eric Guérin; Christine Macabre; Sonia Ledrappier; Cyril Bour; Christine Wasylyk; Nelly Etienne-Selloum; Laurent Brino; Christian Gaiddon; Bohdan Wasylyk; Alain C Jung
Journal:  Cancers (Basel)       Date:  2019-06-08       Impact factor: 6.639

8.  Cell-line-specific stimulation of tumor cell aggressiveness by wound healing factors - a central role for STAT3.

Authors:  Lars Ekblad; Gustaf Lindgren; Emma Persson; Elisabeth Kjellén; Johan Wennerberg
Journal:  BMC Cancer       Date:  2013-01-25       Impact factor: 4.430

9.  Intra-tumor AvidinOX allows efficacy of low dose systemic biotinylated Cetuximab in a model of head and neck cancer.

Authors:  Loredana Vesci; Ferdinando Maria Milazzo; Anna Maria Anastasi; Fiorella Petronzelli; Caterina Chiapparino; Valeria Carollo; Giuseppe Roscilli; Emanuele Marra; Laura Luberto; Luigi Aurisicchio; Maria Lucrezia Pacello; Luigi Giusto Spagnoli; Rita De Santis
Journal:  Oncotarget       Date:  2016-01-05

10.  FGFR signaling regulates resistance of head and neck cancer stem cells to cisplatin.

Authors:  Sarah C McDermott; Christie Rodriguez-Ramirez; Sean P McDermott; Max S Wicha; Jacques E Nör
Journal:  Oncotarget       Date:  2018-05-18
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.